Sandoz Group AG (Sandoz Group AG) Marketable Securities : $0 Mil (As of Dec. 2023)

View and export this data going back to 2023. Start your Free Trial

What is Sandoz Group AG Marketable Securities?

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price. Sandoz Group AG's Marketable Securities for the quarter that ended in Dec. 2023 was $0 Mil.

Sandoz Group AG Marketable Securities Historical Data

The historical data trend for Sandoz Group AG's Marketable Securities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sandoz Group AG Marketable Securities Chart

Sandoz Group AG Annual Data

Trend

Dec22

Dec23

Marketable Securities

Sandoz Group AG Quarterly Data
	Dec22	Dec23
Marketable Securities	-	-

Sandoz Group AG Marketable Securities Calculation

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price.

Sandoz Group AG (OTCPK:SDZNY) Marketable Securities Explanation

Marketable Securities are very liquid as they tend to have maturities of less than one year. Furthermore, the rate at which these securities can be bought or sold has little effect on their prices.

Please note, GuruFocus' Marketable Securities also includes "Other Short Term Investment".

Sandoz Group AG Marketable Securities Related Terms

Thank you for viewing the detailed overview of Sandoz Group AG's Marketable Securities provided by GuruFocus.com. Please click on the following links to see related term pages.

Sandoz Group AG (Sandoz Group AG) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Sandoz Group AG (OTCPK:SDZNY) » Definitions » Marketable Securities

Comparable Companies

Traded in Other Exchanges

SDZXF:USA SDZz:UK D8Y0:Germany SDZ:Switzerland

Address

Forum 1, Novartis Campus, Basel, CHE, CH-4056

Website

https://www.sandoz.com

Sandoz is one of the largest generic pharmaceutical manufacturers in the world, generating over $9 billion annually from off-patent drugs. Once part of Novartis, Sandoz spun off and went public in October 2023. Generics, including small molecules and complex injectables, make up roughly 75% of Sandoz's total sales, and the firm has a significant presence in Europe, the United States, and other key international markets. Sandoz generates its remaining sales from biosimilars and is among leaders in the space. Sandoz launched Europe's first biosimilar, Omnitrope, in 2006 as well as U.S.'s first biosimilar, Zarxio, in 2015. It currently has eight commercialized biosimilars in a number of markets and has over 20 assets in pipeline.

Sandoz Group AG (Sandoz Group AG) Headlines

From GuruFocus

Q3 2023 Sandoz Group AG Earnings Call Transcript

By GuruFocus Research • 02-14-2024

Q3 2023 Sandoz Group AG Earnings Call Transcript

By GuruFocus Research • 02-14-2024